Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177999 | 0.84 | TDP1 (0.33) | IDO1TAAR1CA2 | |
| SCHEMBL22801232 | 0.83 | TAAR1 (0.42) | MAOBMAOATRPA1TAAR1AOC3 | |
| SCHEMBL22801194 | 0.82 | IDO1 (0.52) | IDO1 | |
| SCHEMBL1060869 | 0.82 | IDO1 (0.42) | IDO1AGXTMAOBMAOAAPP | |
| SCHEMBL21178000 | 0.82 | IDO1 (0.42) | IDO1MAOB | |
| SCHEMBL2252915 | 0.81 | TSHR (0.41) | IDO1AGXTMAOATAAR1CA1 | |
| SCHEMBL21179052 | 0.81 | MAOB (0.39) | MAOBMAOA | |
| SCHEMBL21178030 | 0.80 | IDO1 (0.49) | IDO1AGXTMAOBMAOATAAR1 | |
| SCHEMBL22801183 | 0.80 | TAAR1 (0.40) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22801241 | 0.79 | APP (0.41) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2019143860-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | IDO1 4055/4885AGXT 791/4885MAOB 846/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | IDO1 3948/4885AGXT 926/4885MAOB 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.